Canadian Cancer Trials Group Bulletins


Recent Publications

HD.8 (EORTC 20012) - BEACOPP (4 cycles escalated + 4 cycles baseline) Versus ABVD (8 cycles) in Stage III & IV Hodgkin's Lymphoma

The purpose of this study was to compare patients with high-risk stage III to IV Hodgkin lymphoma (HL) who were randomly assigned to either doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). Between 2002 and 2010, 549 patients were randomly assigned to either ABVD or BEACOPP (n = 274).

The authors found that ABVD and BEACOPP resulted in similar event-free survival and overall survival in patients with high-risk advanced-stage HL. Because BEACOPP did not demonstrate a favorable effectiveness or toxicity ratio compared with ABVD, treatment burden, immediate and late toxicities, and associated costs must be considered before selecting one of these regimens on which to build future treatment strategies.

Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score > 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial (ONLINE). J Clin Oncol 2016.

MA.14 - A Randomized Trial of Antiestrogen Therapy versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 (ONLINE). Breast Cancer Res Treat 1-8, 2016.

MA.27 - A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

Chapman JA, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA, Whelan TJ, Elliott C, Goss PE. Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Res Treat 156: 343-9, 2016

Hay AE, Rae C, Fraser GA, Meyer RM, Abbott LS, Bevan S, McBride ML, Cuvelier GDE, McKillop S, Barr RD. Accrual of adolescents and young adults with cancer to clinical trials. Curr Oncol 23: e81-e85, 2016.